Fulgent Genetics (FLGT) AI Stock Analysis

• Market Cap: $864.62M
• Dividend Yield: N/A
• Average Volume (3M): 197.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: 13.60%
• EPS Growth: 74.64%
• Country: US
• Employees: 1,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.14
• Shares Outstanding: 30,912,392
• 10 Day Avg. Volume: 196,532
• 30 Day Avg. Volume: 197,329
• PEG Ratio: 0.17
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 1.97
• P/FCF Ratio: -29.00
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 1.83
• Enterprise Value/Gross Profit: 4.44
• Enterprise Value/Ebitda: -18.48
• 1Y Price Target: $32.50
• Price Target Upside: 16.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.47
• Revenue Forecast (FY): $356.33M

• Rating: 53 Neutral
• Price Target: $28.00 ▲(0.11% Upside)

The score is held back primarily by weak financial performance (ongoing losses and cash flow pressure), partially offset by a strong low-leverage balance sheet. Technicals are neutral-to-mildly supportive, while valuation is constrained by unprofitability and no dividend. The latest earnings call and recent strategic acquisitions improve the outlook via raised revenue/margin expectations and platform expansion, but they have not yet translated into strong GAAP profitability.

Positive Factors

Strategic Acquisitions

The acquisitions expand Fulgent's dermatopathology services, enhancing its diagnostics platform and broadening its market reach, supporting long-term growth.

Revenue Growth

The increased revenue guidance reflects strong business momentum and operational efficiencies, indicating robust demand for Fulgent's services.

Product Innovation

New product launches in precision diagnostics enhance Fulgent's service offerings, potentially improving diagnostic yield and patient outcomes, strengthening its competitive position.

Negative Factors

Cash Flow Challenges

Persistent cash flow issues can limit Fulgent's ability to invest in growth opportunities and may strain its financial flexibility over time.

Profitability Issues

Ongoing GAAP losses highlight profitability challenges, which could impact Fulgent's ability to sustain operations without external financing.

Operating Margin Pressure

Negative operating margins suggest efficiency issues, potentially affecting Fulgent's long-term cost structure and competitive pricing strategies.

Fulgent Genetics Business Overview & Revenue Model

Company Description

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

How the Company Makes Money

Fulgent Genetics generates revenue primarily through its genetic testing services, which include various forms of genomic analysis for patients and healthcare providers. The company operates a business model that relies on the sale of its testing kits, laboratory services, and data analytics solutions. Key revenue streams include reimbursement from insurance companies for tests performed, direct payments from healthcare providers, and partnerships with hospitals and clinics that utilize Fulgent's testing solutions for their patients. Additionally, Fulgent has established collaborations with pharmaceutical companies and research institutions, which further enhances its earning potential through joint ventures and research agreements.

Fulgent Genetics Financial Statement Overview

Summary

Fulgent Genetics is facing financial difficulties, with declining revenues and profitability since 2021. The balance sheet remains strong with low leverage, but cash flow issues are concerning. The company needs to address operational inefficiencies and improve cash generation to stabilize its financial position.

Income Statement

Fulgent Genetics has experienced a significant decline in revenue and profitability over the past few years. The TTM data shows a slight revenue growth of 4.07%, but the company is still operating at a loss with a net profit margin of -13.62%. Historical data reveals a sharp decline from 2021, when the company had a net profit margin of 51.12%. The EBIT and EBITDA margins have also deteriorated, indicating operational challenges.

Balance Sheet

The balance sheet remains relatively strong with a very low debt-to-equity ratio of 0.0004 in the TTM period, indicating minimal leverage. However, the return on equity is negative at -3.82%, reflecting the company's current unprofitability. The equity ratio is stable, suggesting a solid capital structure despite recent losses.

Cash Flow

Cash flow metrics indicate challenges, with a significant decline in free cash flow growth and a negative free cash flow to net income ratio of -13.03 in the TTM period. The operating cash flow to net income ratio is low at 0.021, highlighting cash generation issues. Historical data shows a drastic reduction in free cash flow from 2021 levels.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	315.55M	283.47M	289.21M	618.97M	992.58M	421.71M
Gross Profit	130.14M	107.22M	104.46M	366.90M	777.05M	331.90M
EBITDA	-31.26M	-48.99M	-147.45M	217.70M	686.96M	293.12M
Net Income	-42.98M	-42.71M	-167.82M	143.40M	507.36M	214.31M
Balance Sheet
Total Assets	1.21B	1.22B	1.24B	1.39B	1.28B	700.46M
Cash, Cash Equivalents and Short-Term Investments	375.80M	258.11M	424.15M	526.24M	450.50M	299.37M
Total Debt	7.54M	8.47M	15.25M	38.94M	21.28M	15.85M
Total Liabilities	93.81M	90.81M	102.04M	116.18M	112.84M	131.07M
Stockholders Equity	1.13B	1.13B	1.14B	1.27B	1.16B	569.39M
Cash Flow
Free Cash Flow	-19.85M	-19.25M	4.80M	234.75M	514.73M	104.12M
Operating Cash Flow	1.52M	21.06M	27.00M	253.52M	538.58M	140.63M
Investing Cash Flow	72.76M	-58.35M	38.90M	-261.31M	-546.55M	-326.44M
Financing Cash Flow	-14.58M	-4.85M	-47.78M	-77.14M	85.41M	261.25M

Fulgent Genetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 27.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLGT, the sentiment is Positive. The current price of 27.97 is above the 20-day moving average (MA) of 27.17, above the 50-day MA of 27.53, and above the 200-day MA of 22.24, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 56.47 is Neutral, neither overbought nor oversold. The STOCH value of 91.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLGT.

Fulgent Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$1.05B	17.04	24.11%	―	14.46%	―
CSTL	62 Neutral	$1.19B	-90.58	-2.69%	―	10.15%	-295.52%
FLGT	53 Neutral	$864.62M	-19.96	-3.80%	―	13.60%	74.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PSNL	49 Neutral	$825.88M	-10.62	-43.69%	―	-21.02%	47.74%
LAB	47 Neutral	$611.46M	-4.70	-24.63%	―	-17.37%	52.28%
MYGN	41 Neutral	$569.54M	-1.41	-72.52%	―	0.21%	-233.51%

Fulgent Genetics Corporate Events

Fulgent Genetics expands diagnostics with major dermatopathology deals

On December 20, 2025, Fulgent Genetics’ subsidiary Inform Diagnostics signed agreements to buy all equity interests in Dermatopathology Experts (StrataDx) for $12.5 million and to acquire substantially all assets and certain liabilities of Bako Diagnostics’ dermatopathology, podiatric pathology, molecular diagnostic services and therapeutic products business for $43 million, for a total cash consideration of about $55.5 million, with closing targeted for the first half of 2026 subject to customary regulatory and closing conditions and mutual termination rights. The planned acquisitions will add CLIA- and CAP-accredited pathology laboratories in Georgia and Massachusetts, broaden Fulgent’s anatomic and dermatopathology test menu with proprietary PCR assays, nearly double its pathology salesforce, and deepen its national client base, reinforcing its push to become a one-stop diagnostic provider and to leverage its investments in AI-driven digital pathology to improve capacity, turnaround times and efficiency across its growing laboratory services platform.

The most recent analyst rating on (FLGT) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.

Fulgent Genetics Raises 2025 Revenue Guidance

Fulgent Genetics reported its third quarter 2025 financial results, showing a revenue of $84.1 million, a 17% increase year-over-year, and a GAAP loss of $6.6 million. The company raised its full-year 2025 revenue guidance to $325.0 million and expects to end the year with approximately $800.0 million in cash and investments, demonstrating strong momentum in its laboratory services and therapeutic development businesses.

The most recent analyst rating on (FLGT) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.

Fulgent Genetics Presents Promising Phase 2 Trial Data

On October 20, 2025, Fulgent Genetics announced preliminary clinical data from its ongoing phase 2 trial of FID-007 in combination with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO 2025 Conference, showed promising anticancer efficacy and a favorable safety profile, suggesting potential advancements in oncology treatments. This development supports Fulgent’s mission to provide comprehensive cancer care solutions, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (FLGT) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.